Saltar al contenido
Merck
Todas las fotos(1)

Documentos

V0033000

Valproic acid

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2-Propylpentanoic acid, Valproic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula lineal:
(CH3CH2CH2)2CHCO2H
Número de CAS:
99-66-1
Peso molecular:
144.21
MDL number:
MFCD00002672
UNSPSC Code:
41116107
PubChem Substance ID:
329828882
NACRES:
NA.24

grade

pharmaceutical primary standard

agency

EP Reference Standard

API family

valproic acid

manufacturer/tradename

EDQM

refractive index

n20/D 1.425 (lit.)

bp

220 °C (lit.)

density

0.9 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCCC(C(O)=O)CCC

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

InChI key

NIJJYAXOARWZEE-UHFFFAOYSA-N

Gene Information

human ... ALDH5A1(7915)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Valproic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anticonvulsant that also has efficacy as a mood stabilizer in bipolar disorder

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 1A - Skin Irrit. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

231.8 °F - closed cup

flash_point_c

111 °C - closed cup

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 1

1 of 1

Levetiracetam European Pharmacopoeia (EP) Reference Standard

Y0001253

Levetiracetam

Mattias Linde et al.
The Cochrane database of systematic reviews, 6(6), CD010611-CD010611 (2013-06-26)
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an
Chi-Tso Chiu et al.
Pharmacological reviews, 65(1), 105-142 (2013-01-10)
The mood stabilizers lithium and valproic acid (VPA) are traditionally used to treat bipolar disorder (BD), a severe mental illness arising from complex interactions between genes and environment that drive deficits in cellular plasticity and resiliency. The therapeutic potential of
Radu M Nanau et al.
Clinical biochemistry, 46(15), 1323-1338 (2013-06-25)
Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmacoeconomic profiles, as well as a relatively favorable safety profile. However, adverse drug reactions have been reported in relation with
Florence I Roullet et al.
Neurotoxicology and teratology, 36, 47-56 (2013-02-12)
Valproic acid (VPA) is both an anti-convulsant and a mood stabilizer. Clinical studies over the past 40 years have shown that exposure to VPA in utero is associated with birth defects, cognitive deficits, and increased risk of autism. Two recent
Ivana Rosenzweig et al.
Neuroscience and biobehavioral reviews, 36(8), 1848-1856 (2012-06-02)
Neuropsychiatric medications that directly alter the epigenome, such as valproic acid, can under certain conditions reactivate critical developmental periods and thus impact adult neuroconnectivity. In animal models valproic acid was shown to inhibit the process of postnatal myelination and to
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico